Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program

被引：3
|
作者：
Uttervall, Katarina [1 ,2 ]
Nahi, Hareth [2 ,3 ]
Kashif, Muhammad [2 ]
Lemonakis, Konstantinos [4 ]
Rosengren, Sara [5 ]
Brolin, Janaki [6 ]
Lund, Johan [2 ,7 ]
Hansson, Markus [8 ,9 ]
机构：
[1] Karolinska Univ Hosp, Hematol Med Unit, Stockholm, Sweden
[2] Karolinska Inst, Dept Med, Stockholm, Sweden
[3] Genmab AS, Copenhagen, Denmark
[4] Skane Univ Hosp, Dept Hematol, Lund, Sweden
[5] Uppsala Univ Hosp, Dept Hematol, Uppsala, Sweden
[6] Karlstad Cent Hosp, Dept Internal Med, Karlstad, Sweden
[7] Karolinska Univ Hosp, Haematol Ctr, Stockholm, Sweden
[8] Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden
[9] Univ Gothenburg, Dept Internal Med & Clin Nutr, Gothenburg, Sweden
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158801
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12605 / 12606
页数：2
相关论文
共 50 条
  • [21] Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma
    Jandial, Aditya
    Mishra, Kundan
    Lad, Deepesh
    Prakash, Gaurav
    Khadwal, Alka
    Malhotra, Pankaj
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1102 - 1104
  • [22] The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience
    Charlinski, Grzegorz
    Grzasko, Norbert
    Jurczyszyn, Artur
    Janczarski, Mariusz
    Szeremet, Agnieszka
    Waszczuk-Gajda, Anna
    Bernatowicz, Pawel
    Swiderska, Alina
    Guzicka-Kazimierczak, Renata
    Lech-Maranda, Ewa
    Szczepaniak, Andrzej
    Wichary, Ryszard
    Dmoszynska, Anna
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (03) : 354 - 361
  • [23] Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
    Hansen, Doris K.
    Sidana, Surbhi
    Peres, Lauren C.
    Leitzinger, Christelle Colin
    Shune, Leyla
    Shrewsbury, Alexandria
    Gonzalez, Rebecca
    Sborov, Douglas W.
    Wagner, Charlotte
    Dima, Danai
    Hashmi, Hamza
    Kocoglu, Mehmet H.
    Atrash, Shebli
    Simmons, Gary
    Kalariya, Nilesh
    Ferreri, Christopher
    Afrough, Aimaz
    Kansagra, Ankit
    Voorhees, Peter
    Baz, Rachid
    Khouri, Jack
    Alsina, Melissa
    McGuirk, Joseph
    Locke, Frederick L.
    Patel, Krina K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 2087 - +
  • [24] Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
    Shragai, Tamir
    Magen, Hila
    Lavi, Noa
    Gatt, Moshe
    Trestman, Svetlana
    Zektser, Miri
    Ganzel, Chezi
    Jarchowsky, Osnat
    Berger, Tamar
    Tadmor, Tamar
    Leiba, Merav
    Hertzog-Tzarfaty, Katrin
    Horowitz, Netanel
    Shapira, Michael
    Varssano, David
    Berger, Yoav
    Frenkel, Shahar
    Krauthammer, Mark
    Avivi, Irit
    Luttwak, Efrat
    Cohen, Yael C.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (01) : 45 - 53
  • [25] Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience
    Byun, Ja Min
    Yoon, Sung-Soo
    Koh, Youngil
    Kim, Inho
    Jo, Jaemin
    Park, Hyunkyung
    Lee, Jeong-Ok
    Lee, Jiyun
    [J]. ANTICANCER RESEARCH, 2019, 39 (09) : 5165 - 5170
  • [26] Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma
    Becnel, Melody
    Ferreri, Christopher
    Feng, Lei
    Richards, Tiffany
    Horowitz, Sandra
    Patel, Nimisha
    Gombos, Dan
    Razmandi, Azadeh
    Murga, Astrid
    Seif, Sherif
    Youssef, George
    Murphy, Kevin
    Kaufman, Gregory
    Weber, Donna
    Patel, Krina
    Thomas, Sheeba
    Manasanch, Elisabet
    Orlowski, Robert
    Lee, Hans
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S163 - S164
  • [27] BCMA x CD3 bispecific antibody treatment with teclistamab in relapsed and/or refractory multiple myeloma: a real-world monocentric analysis
    Schaefers, C.
    Thiele, B.
    Alsdorf, W.
    Kosch, R.
    Leypoldt, L.
    Bokemeyer, C.
    Weisel, K.
    Kamili, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 312 - 312
  • [28] Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
    Adrián Alegre
    Gonzalo Benzo
    Rafael Alonso
    Joaquín Martínez-López
    Ana Jimenez-Ubieto
    Clara Cuéllar
    Elham Askari
    Elena Prieto
    Concepción Aláez
    Beatriz Aguado
    Alberto Velasco
    Isabel Krsnik
    Ana Bocanegra
    Laura Llorente
    Cristina Muñoz-Linares
    Ana Morales
    Eugenio Giménez
    Rebeca Iglesias
    Carmen Martínez-Chamorro
    Aránzazu Alonso
    Carmen Jiménez-Montes
    María J. Blanchard
    [J]. Oncology and Therapy, 2023, 11 : 83 - 96
  • [29] Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
    Alegre, Adrian
    Benzo, Gonzalo
    Alonso, Rafael
    Martinez-Lopez, Joaquin
    Jimenez-Ubieto, Ana
    Cuellar, Clara
    Askari, Elham
    Prieto, Elena
    Alaez, Concepcion
    Aguado, Beatriz
    Velasco, Alberto
    Krsnik, Isabel
    Bocanegra, Ana
    Llorente, Laura
    Munoz-Linares, Cristina
    Morales, Ana
    Gimenez, Eugenio
    Iglesias, Rebeca
    Martinez-Chamorro, Carmen
    Alonso, Aranzazu
    Jimenez-Montes, Carmen
    Blanchard, Maria J.
    [J]. ONCOLOGY AND THERAPY, 2023, 11 (01) : 83 - 96
  • [30] Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
    Huang, Shang-Yi
    Chen, Tsai-Yun
    Kuo, Ching-Yuan
    Chen, Yeu-Chin
    Lin, Sheng-Fung
    Chang, Ming-Chih
    Lv, Xinzhu
    Yang, Betty
    Chang, Cheng-Shyong
    [J]. ONCOLOGY REVIEWS, 2019, 13 (01) : 15 - 22
12345